Current concepts of breast cancer prevention in patients with proliferative disorders of the reproductive system

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review discusses the current concepts in estrogen-dependent proliferation, with relation to the molec­ular markers of proliferative disorders. We emphasize the rationale for wider use of the invasive diagnostics in the assessment of the mammary glands status. The data on breast cancer prevention in patients with benign proliferative disorders of the reproductive system is summarized. The use of ovarian suppression dur­ing reproductive period (GnRH agonists) and aromatase inactivation (aromatase inhibitors) is substantiated. The mechanisms of action of selective estrogen receptor modulators used in breast cancer treatment and prevention are discussed. The designs and results of all phase III-IV breast cancer chemoprevention trials are reported.

About the authors

Е. К. Ailamazyan

Ott Institute of Obstetrics and Gynecology of the Russian Academy of Medical Sciences; N. N. Petrov Institute of Oncology; St. Petersburg State University

Author for correspondence.
Email: shabanov@mail.rcom.ru

академик РАМН

Russian Federation, St. Petersburg; St. Petersburg; St. Petersburg

V. F. Semiglazov

Ott Institute of Obstetrics and Gynecology of the Russian Academy of Medical Sciences; N. N. Petrov Institute of Oncology; St. Petersburg State University

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg; St. Petersburg; St. Petersburg

Е. N. Baylyuk

Ott Institute of Obstetrics and Gynecology of the Russian Academy of Medical Sciences; N. N. Petrov Institute of Oncology; St. Petersburg State University

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg; St. Petersburg; St. Petersburg

D. A. Niauri

Ott Institute of Obstetrics and Gynecology of the Russian Academy of Medical Sciences; N. N. Petrov Institute of Oncology; St. Petersburg State University

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg; St. Petersburg; St. Petersburg

I. M. Kvetnoy

Ott Institute of Obstetrics and Gynecology of the Russian Academy of Medical Sciences; N. N. Petrov Institute of Oncology; St. Petersburg State University

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg; St. Petersburg; St. Petersburg

V. G. Ivanov

Ott Institute of Obstetrics and Gynecology of the Russian Academy of Medical Sciences; N. N. Petrov Institute of Oncology; St. Petersburg State University

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg; St. Petersburg; St. Petersburg

A. G. Manikhas

Ott Institute of Obstetrics and Gynecology of the Russian Academy of Medical Sciences; N. N. Petrov Institute of Oncology; St. Petersburg State University

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg; St. Petersburg; St. Petersburg

A. A. Soshnev

Ott Institute of Obstetrics and Gynecology of the Russian Academy of Medical Sciences; N. N. Petrov Institute of Oncology; St. Petersburg State University

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg; St. Petersburg; St. Petersburg

References

  1. Берштейн Л. М. Онкоэндокринология: традиции, современность и перспективы. СПб., 2004. 343 с.
  2. Волобуев А. И., Синицын В. А., Малышева В. А. и др. Результаты обследования женщин с сочетанными доброкачественными гиперпластическими процессами молочных желез и половых органов // Акуш. и гин. 2003. № 5. С. 27-31.
  3. Мерабишвили В. М.. Старинский В. В., Петрова Г В. w др. Злокачественные новообразования в Северо-Западном Федеральном округе России. СПб., 2005. 312 с.
  4. Семиглазов В. Ф., Семиглазов В. В., Клецезь А. Е. Неинвазивные и инвазивные опухоли молочной железы. СПб., 2005. 350 с.
  5. Семиглавое В. Ф., Нургазиев К. Ш., Арзуманов А. С. Опухоли молочной железы (лечение и профилактика). Алматы, 2001.344 с.
  6. Упоров А. В.. Семиглазов В. Ф., Пожарийсский К. М. Иммуногистохимическое изучение клеток рака молочной железы с использованием разных маркеров пролиферации // Архив патол. 2000. № 2. С. 26-30.
  7. Харченко В. П.. Рожкова Н. И. Инвазивные методы при исследовании молочной железы // Вести, рентгенол. и радиол. 2003. № 3. С. 21-27.
  8. ХасхановаЛ. X.. Пиддубный М. И.. Гуриев Т. Д. Мастопатия и гинекологические заболевания // Акуш. и гин. 1998. № 1. С. 57-61.
  9. Atalay G., Dirix L.. Biganzoli L. et al. The effect of exemestane on serum lipid profile in post-menopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, ‘Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients’ // Ann. Oncol. 2004. Vol. 15. P. 211-217.
  10. Baisch H., Gerdes J. Identification of proliferating cells by Ki-67 antibody // Methods Cell Biol. 1990. Vol. 33. P. 217-226.
  11. Bilimoria M. M„ Morrow M. The woman at increased risk for breast cancer: evaluation and management strategies // CA Cancer J. Clin. 1995. Vol. 5. P. 263-278.
  12. Burnett S. J.. Ng Y. Y, Perry N. M et al. Benign biopsies in the prevalent round of breast screening: review of 137 cases // Clin. Radiol. 1995. Vol. 50. P. 254-258.
  13. Castro-Rivera E., Samudio I.. Safe S. Estrogen regulation of cyclin DI gene expression in ZR-75 breast cancer cells involves multiple enhancer elements // J. Biol. Chcm. 2001. Vol. 276. P. 30853-30861.
  14. Chhieng D. C., Frost A. R.. Niwas S. et al. Intratumor heterogeneity of biomarker expression in breast carcinomas // Biotech. Histochem. 2004. Vol. 79. P. 25-36.
  15. Claus Е. В., Risch N. J., Thompson W. D. Age at onset as an indicator of familial risk of breast cancer // Am. J. Epidemiol. 1990. Vol. 131. P. 961-972.
  16. Colditz G. A., Rosner B. A., Chen IV. Y. et al. Risk factors for breast cancer according to estrogen and progesterone receptor status // J. Natl. Cancer Inst. 2004. Vol. 96. P. 218-228.
  17. Coradini D., Daidone M. G. Biomolecular prognostic factors in breast cancer // Curr. Opin. Obstet. Gynecol. 2004. Vol. 16. P. 49-55.
  18. Cowley S. M., Parker M. G. A comparison of transcriptional activation by ER alpha and ER beta // J. Steroid. Biochem. Mol. Biol. 1999. Vol. 69. P. 165-175.
  19. Cummings S. R., Eckert S., Krueger K. A. et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial: Multiple Outcomes of Raloxifene Evaluation // JAMA. 1999. Vol. 281. P. 2189-2197. Erratum in: JAMA. 1999. Vol. 282. P. 2124.
  20. Cuzick J. Aromatase inhibitors in prevention - data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IB1S-II (the second International Breast Cancer Intervention Study) // Recent Results Cancer Res. 2003. Vol. 163. P. 96-103. Discussion: P. 264-266.
  21. Cuzick J., Forbes J., Edwards R. et al. First results from the International Breast Cancer Intervention Study (1BIS-I): a randomised prevention trial // Lancet. 2002. Vol. 3 60. P. 817-824.
  22. Cuzick J., Baum M. Tamoxifen and contralateral breast cancer// Lancet. 1985. Vol. 2. P. 282.
  23. Dietrich D. R. Toxicological and pathological applications of proliferating cell nuclear antigen (PCNA), a novel endogenous marker for cell proliferation // Crit. Rev. Toxicol. 1993. Vol. 23. P. 77-109.
  24. di Salle E., Ornati G., Giudici D. et al. Exemestane (FCE 24304). a new steroidal aromatase inhibitor//J. Steroid. Biochem. Mol. Biol. 1992. Vol. 43. P. 137-143.
  25. Dixon D., Flake G. P.. Moore A. B. et al. Cell proliferation and apoptosis in human uterine leiomyomas and myometria // Virchows Arch. 2002. Vol. 441. P. 53-62.
  26. Dumitrescu R. G., Colarla 1. Understanding breast cancer risk - where do we stand in 2005? //J. Cell. Mol. Med. 2005. Vol. 9. P. 208-221.
  27. ElisafM. S.. Bairaktari E. T., Nicolaides C. et al. Effect of letrozole on the lipid profile in post-menopausal women with breast cancer // Eur. J. Cancer. 2001. Vol. 37. P. 1510-1513.
  28. Fisher B., Costantino J. P, Wickerham D. L. et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-l study // J. Natl. Cancer Inst. 2005. Vol. 97. P. 1652-1662.
  29. Fisher B., Costantino J. P, Wickerham D. L. etal. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l Study // J. Natl. Cancer Inst. 1998. Vol. 90. P. 1371-1388.
  30. Gail M. H., Brinton L. A., Byar D. P. et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually // J. Natl. Cancer. Inst. 1989. Vol. 81. P. 1879-1886.
  31. Geisler J., KingN, Anker G. et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients // Clin. Cancer Res. 1998. Vol. 4. P. 2089-2093.
  32. Goehring C., Morabia A. Epidemiology of benign breast disease, with special attention to histologic types//Epidemiol. Rev. 1997. Vol. 19. P. 310-327.
  33. Goss P. E., Ingle J. N.. Martino S. et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17 // J. Natl. Cancer Inst. 2005. Vol. 97. P. 1262-1271.
  34. Goss P. E., Strasser-Weippl K. Aromatase inhibitors for chemoprevention // Best Pract. Res. Clin. Endocrinol. Metab. 2004. Vol. 18. P. 113-130.
  35. Goss P. E„ Qi S., Josse R. G. et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats // Bone. 2004. Vol. 34. P. 384-392.
  36. Harper-Wynne C.. Ross G., Sacks N. et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention // Cancer Epidemiol. Biomarkers Prev. 2002. Vol. 11. P. 614-621.
  37. Hartmann L.C., Sellers T. A., Frost M. H. et al. Benign breast disease and the risk of breast cancer //N. Engl. J. Med. 2005. Vol. 353. P. 229-237.
  38. Henriksen R., Strang P. Wilander E. et al. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry // Gynecol. Oncol. 1994. Vol. 53. P. 301-306.
  39. Howell A.. Cuzick J.. Baum M. et al. Results of the ATAC (Arimidex. Tamoxifen. Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer // Lancet. 2005. Vol. 365. P. 60-62.
  40. Howell A., Dowsett М. Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens // Breast Cancer Res. 2004. Vol. 6. P. 269-274.
  41. Ikeda K., Inoue S. Estrogen receptors and their downstream targets in cancer // Arch. Histol. Cytol. 2004. Vol. 67. P. 435-442.
  42. Jubelirer S. J., Crowell E. B. Jr. The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia // W. V. Med. J. 2000. Vol. 96. P. 602-604.
  43. Kristensen V. N., Sortie T., Geisler J. et al. Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications // Clin. Cancer Res. 2005. Vol. 11. P. 878S-883S.
  44. Kuiper G. G., Enmark E., Pelto-Huikko M. et al. Cloning of a novel receptor expressed in rat prostate and ovary // Proc. Natl. Acad. Sci. USA. 1996. Vol. 93. P. 5925-5930.
  45. League E., Dotzlaw H., Watson P. H, Murphy L. C. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis // Cancer Res. 1998. Vol. 58. P. 3197-3201.
  46. Lonning P. E. Aromatase inhibition for breast cancer treatment // Acta Oncol. 1996. Vol. 35 (Suppl. 5). P. 38-43.
  47. Maia Jr. H., Maltez A.. Studart E. et al. Effect of menstrual cycle and hormonal treatment on ki-67 and bcl-2 expression and adenomyosis // Gynecol. Endocrinol. 2005. Vol. 20. P. 127-131.
  48. Mann B. S., Johnson J. R., Kelly R. et al. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen H Clin. Cancer Res. 2005. Vol. 11. P. 5671-5677.
  49. Marchetti P, Di Rocco C. Z., Ricevuto E. et al. Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama // Ann. Oncol. 2004. Vol. 15 (Suppl. 1). P. 127-134.
  50. Maruo T., Ohara N„ Wang J.. Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis // Hum. Reprod. Update. 2004. Vol. 10. P. 207-220.
  51. McTiernan A., Kuniyuki A.. Yasui Y et al. Comparisons of two breast cancer risk estimates in women with a family history of breast cancer // Cancer Epidemiol. Biomarkers Prev. 2001. Vol. 10. P. 333-338.
  52. Nathanson K. L., Wooster R., Weber B. L. Breast cancer genetics: what we know and what we need // Natl. Med. 2001. Vol. 7. P. 552-556.
  53. Nieburg H. E. Cancer Prevention & Control Strategy Resolution adopted by the 58th World Health Assembly, Geneva, May 25, 2005 // Cancer Detect. Prevent. 2005. Vol. 29. P. 403-404.
  54. Nilsson S., Makela S., Treuter E. et al. Mechanisms of estrogen action // Physiol. Rev. 2001. Vol. 81. P. 1535-1565.
  55. Ohmichi M., Tasaka K, Kurachi H.. Murata Y. Molecular mechanism of action of selective estrogen receptor modulator in target tissues // Endocr. J. 2005. Vol. 52. P. 161-167.
  56. Paech K, Webb P. Kuiper G. G. et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at API sites // Science. 1997. Vol. 277. P. 1508-1510.
  57. Potgieter H. C., Magagane E, Bester M. J. Oestrogen and progesterone receptor status and PgR/ER ratios in normal and myomatous human myometrium // East Afr. Med. J. 1995. Vol. 72. P. 510-514.
  58. Powles T. J. Anti-oestrogenic prevention of breast cancer - the make or break point // Nat. Rev. Cancer. 2002. Vol. 2. P. 787-794. Erratum in: Nat. Rev. Cancer. 2002. Vol. 2. P. 964.
  59. Powles T. J. The Royal Marsden Hospital (RMH) trial: key points and remaining questions // Ann. NY Acad. Sci. 2001. Vol. 949. P. 109-112.
  60. Powles T. J.. Eeles R.. Ashley S. et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial // Lancet. 1998. Vol. 352. P. 98-101.
  61. Powles T. J., Hardy J. R.. Ashley S. E. et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer// Br. J. Cancer. 1989. Vol. 60. P. 126-131.
  62. Roger P. Sah/a M E., Makela S. etal. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors // Cancer Res. 2001. Vol. 61. P. 2537-2541.
  63. Santen R. J.. Mansel R. Benign Breast Disorders //N. Engl. J. Med. 2005. Vol. 353. P. 275-285.
  64. Santen R. J. The potential of aromatase inhibitors in breast cancer prevention // Endocr. Relat. Cancer. 1999. Vol. 6. P. 235-243.
  65. Schiff R., Massarweh S., Shou J., Osborne С. K. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response // Clin. Cancer Res. 2003. Vol. 9. P. 447S-454S.
  66. Schiff R., Massarweh S. A.. Shou J. et al. Crosstalk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance I/ Clin. Cancer Res. 2004. Vol. 10. P. 331S-336S.
  67. Semiglazov V. Е, Semiglazov V. V., Ivanov И G. Preoperative hormonal therapy vs chemotheraqpy in postmenopausal ER-positive breast cancer patiens // EJC. 2004. Vol. 2. P. 51-71.
  68. Semiglazov V. E New approaches to neoadjuvant therapy // ASCO. New Orleans. 2004. Selections oral presentations. P. 72-75.
  69. Semiglazov V. E, Kletzel A. E., Semiglazov V. V. et al. Exemestane vs Tamoxifen as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-L T4N0M0)//41 Annual Meeting. ASCO. Orlando (USA). 2005. P. 530S.
  70. Shaaban A. M., Sloane J. P., West C. R., Eoster C. S. Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression H Am. J. Pathol. 2002. Vol. 160. P. 597-604.
  71. Stoll B. A. Premalignant breast lesions: role for biological markers in predicting progression to cancer // Eur. J. Cancer. 1999. Vol. 35. P. 693-697.
  72. Stolier A. J., Rupley D. G. The impact of image-directed core biopsy on the practice of breast surgery: a new algorithm for a changing technology // Am. Surg. 1997. Vol. 63. P. 827-830.
  73. Swiatecka J., Laudanski R. Dzieciol J. Fine needle aspiration cytology of benign breast disease: Markers of apoptosis and proliferation // Neo¬plasma. 2004. Vol. 51. P. 49-55.
  74. The Breast International Group (BIG) 1-98 Collaborative Group. A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer // N. Engl. J. Med. 2005. Vol. 353. P. 2747-2757.
  75. Tobias J. S. Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention //Ann. Oncol. 2004. Vol. 15. P. 1738-1747.
  76. Tsai M., O'Malley B. Molecular mechanisms of action of steroid/thyroid receptor superfamily members H Ann. Rev. Biochem. 1994. Vol. 63. P. 451-486.
  77. Tyrer J., Duffy S. W., Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors // Stat. Med. 2004. Vol. 23. P. 1111-1130. Erratum in: Stat. Med. 2005. Vol. 24. P. 156.
  78. Veronesi U., Maisonneuve R, Costa A. et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women: Italian Tamoxifen Prevention Study H Lancet. 1998. Vol. 352. P. 93-97.
  79. Veronesi U„ Maisonneuve R, Rotmensz N. et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women H J. Natl/ Cancer Inst. 2003. Vol. 95. P. 160-165.
  80. Wasan K. M.f Goss P. E„ Pritchard P. H. et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L) // Ann. Oncol. 2005. Vol. 16. P. 707-715.
  81. http://bcra.nci.nih.gov/brc/

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2006 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.